Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy

Diabetologia

Volumn 46, Issue 3, 2003, Pages 394-400

  Boehm, B O ^a   Lang, G ^a   Volpert, O ^b   Jehle, P M ^a   Kurkhaus, A ^a   Rosinger, S ^a   Lang, G K ^a   Bouck, N ^b  

^a UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Angiogenesis; Angiogenic inhibitors; Aqueous humor; Diabetic retinopathy; Pigment epithelium derived factor (PEDF); Vascular endothelial growth factor (VEGF)

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIDIABETIC AGENT; INSULIN; PIGMENT EPITHELIUM DERIVED FACTOR; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; AQUEOUS HUMOR; ARTICLE; CATARACT EXTRACTION; CELL ACTIVITY; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE MARKER; ENDOTHELIUM CELL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; MALE; PIGMENT EPITHELIUM; PRIORITY JOURNAL;

EID: 0037627630     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-003-1040-9     Document Type: Article

References (39)

1. Klein R (1997) The epidemiology of eye disease. In: Pickup JC, Williams G, (eds) Textbook of Diabetes, 2nd ed, Blackwell Sciences, Oxford 44:1-44.9
2. The Diabetes Control and Complications Trial Research Group (1993) The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
3. The Diabetes Control and Complications Trial Research Group (2000) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 342:381-389
4. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
5. Keen H, Lee ET, Russell D, Miki E, Bennett PH, Lu M and the WHO Multinational Study Group (2001) The appearance of retinopathy and progression to proliferative retinopathy: the WHO multinational study of vascular disease in diabetes. Diabetologia 44:S22-S30
6. Kohner EM (1993) Diabetic retinopathy. BMJ 307:1195-1199
7. Porta M (1996) Endothelium: the main actor in the remodelling of the retinal microvasculature in diabetes. Diabetologia 39:739-744
8. Linsenmeier RA, Braun RD, McRipley MAet al. (1998) Retinal hypoxia in long-term diabetic cats. Invest Ophthalmol Vis Sci 39:1647-1657
9. Adamis AP, Miller JW, Bdernal M-Tet al.(1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445-450
10. Aiello LP, Avery RL, Arrigg PG et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487
11. Yoshida A, Yoshida S, Khalil AK, Ishibashi T, Inomata H (1998) Role of NF-kappaB-mediated interleukin-8 expression in intraocular neovascularization. Invest Ophthalmol Vis Sci 39:1097-1106
12. Aiello LP, Pierce EA, Foley ED et al. (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92:10457-10461
13. Bouck N, Stellmach V, Hsu S (1996) How tumors become angiogenic. Adv Cancer Res 69:135-174
14. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364
15. Dawson DW, Volpert OV, Gillis P et al. (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285:245-248
16. Chader GJ (2001) PEDF: raising both hopes and questions in controlling angiogenesis. Proc Natl Acad Sci USA 98:2122-2124
17. Becerra SP (1997) Structure-function studies on PEDF a noninhibitory serpin with neurotrophic activity. Adv Exp Med Biol 425:223-237
18. Miller AD, Robinson GS, Smith LEH, Becerra SP (2000) Regulation of pigment epithelium-derived factor (PEDF) production by oxygen. Invest Ophthalmol Vis Sci 41 [Suppl]: S869-S874
19. Gao G, Li Y, Zhang D, Gee S, Crosson G, Ma J (2001) Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 489:270-276
20. Bouck N (2002) PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med 8:330-334
21. Cao W, Tombran-Tink J, Elias R, Sezate S, Mrazek D, McGinns JF (2001) In vivo protection of photoreceptors from light damage by pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 42:1646-1652
22. Cayouette M, Smith SB, Becerra SP, Gravel C (1999) Pigment epithelium-derived factor delays the death of photoreceptors in mouse models of inherited retinal degenerations. Neurobiol Dis 6:523-532
23. Holekamp NM, Bouck N, Volpert O (2002) Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol 134:220-227
24. Porta M, Sjoelie A-K, Chaturvedi N et al. (2001) Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 44:2203-2209
25. Anonymous (1998) Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 116:874-886
26. Chantelau E, Kohner EM (1997) Why some cases of retinopathy worsen when diabetic control improves. BMJ 315:1105-1106
27. Polverini PJ, Bouck NP, Rastinejad F (1991) Assay and purification of naturally occurring inhibitor of angiogenesis. Methods Enzymol 198:440-450
28. Spranger J, Osterhoff M, Reimann M et al. (2001) Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 50:2641-2645
29. Okamoto T, Oikawa S, Toyota T (1990) Absence of angiogenesis-inhibitory activity in aqueous humor of diabetic rabbits. Diabetes 39:12-16
30. Gao G, Li Y, Zhang D, Gee S, Crosson G, Ma J (2001) Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 489:270-276
31. Okamoto T, Oikawa S, Toyota T (1990) Absence of angiogenesis-inhibitory activity in aqueous humor of diabetic rabbits. Diabetes 39:12-16
32. Stellmach V, Crawford SE, Zhou W, Bouck N (2001) Prevention of ischemia induced retinopathy by the natural ocular anti-angiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA 98:2593-2597
33. Volpert OV, Zaichuk T, Zhou W et al. (2002) Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nature Med 8:349-357
34. Cayouette M, Smith SB, Becerra SP, Gravel C (1999) Pigment epithelium-derived factor delays the death of photoreceptors in mouse models of inherited retinal degenerations. Neurobiol Dis 6:523-532
35. Bilak MM, Corse AM, Bilak SR, Lehar M, Tombran-Tink J, Kuncl RW (1999) Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamate-mediated neurodegeneration. J Neuropathol Exp Neurol 58:719-728
36. Cao W, Tombran-Tink J, Elias R, Sezate S, Mrazek D, McGinns JF (2001) In vivo protection of photoreceptors from light damage by pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 42:1646-1652
37. Boehm BO, Lang GK, Jehle PM, Feldmann B, Lang GE (2001) Octreotide reduces risk for vitreous hemorrhages and loss of visual acuity in patients with high risk proliferative diabetic retinopathy. Horm Metab Res 33:300-306
38. Spranger J, Hammes H-P, Preissner KT, Schatz H, Pfeiffer AFH (2000) Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy: association with retinal photocoagulation. Diabetologia 43:1404-1407
39. Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro PA (2002) Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 43:2428-2434